Table 1. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer.

Agent	Description	Company
Anti–PD-1
Nivolumab	Fully human IgG4 monoclonal antibody directed against PD-1 on T cells	Bristol-Myers Squibb
Pembrolizumab	Humanized IgG4 monoclonal antibody directed against PD-1 on T cells	Merck
Anti–PD-L1
Atezolizumab	Human IgG1 monoclonal antibody directed against PD-L1 on tumor cells	Genetech/Roche
Durvalumab	Fully human IgG1 monoclonal antibody directed against PD-L1 on tumor cells	Astrazeneca
Anti–CTLA-4
Ipilimumab	Fully human IgG1 monoclonal antibody directed against CTLA-4 on T cells	Bristol-Myers Squibb
Tremelimumab	Fully human IgG2 monoclonal antibody directed against CTLA-4 on T cells	MedImmune/Astrazeneca

PD-1: programmed cell death protein 1; PD-L1: programmed death ligand 1; CTLA-4: cytotoxic T-lymphocyte-associated antigen 4.